Remove category better-business
article thumbnail

Median Tech debuts AI-focused unit for cancer trial support

pharmaphorum

Medical imaging specialist Median Technologies has launched a new business unit that will provide decision-making tools – underpinned by artificial intelligence – for sponsors of clinical trials in oncology. Bringing a new cancer drug to market costs an average of $2.8

FDA 90
article thumbnail

SAVE THE DATE: PMN Fall 2021 Summit: Pharma-Marketing Innovations & Trends of 2021 – Sep. 16th

Pharma Marketing Network

From the perspective of your business, how has telehealth advanced over the past 18 months? What benefits does telehealth afford your business? What has your business done to adapt to this trending modality? Where are we now? What challenges—both new and old—does telehealth bring to the table? What’s next for telehealth?

98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Biogen’s ambitions in gene therapy hit by another failed pivotal trial

pharmaphorum

When Biogen acquired Nightstar Therapeutics in 2019, it added a pair inherited retinal disorder (IRD) gene therapies that it hoped would accelerate a push into the fast-evolving category. .

FDA 105
article thumbnail

Aptar launches digital disease management platform

pharmaphorum

The new disease management platform will allow for better patient treatment adherence tracking, according to the company, which says it will create an “end-to-end” digital health programme that will support patients “from the prevention and diagnosis phases, to disease management, and more, across multiple therapeutic areas.”

article thumbnail

Digital health financing falls to two-year low in first half

pharmaphorum

It may be that some of the more crowded categories will see consolidation start to gather momentum, with larger players buying smaller competitors. Venture investors meanwhile also raised record funds last year, which could be deployed in the years to come. .

Cerner 83
article thumbnail

What Pharmacists Should Know About Medicare Open Enrollment 2024

Digital Pharmacist

Below is a breakdown of what you need to be aware of when assisting patients with 2024 open enrollments, as well as a few tips on how your pharmacy can prepare for this busy time at the pharmacy. With so many plans to choose from, having expert guidance from their pharmacy helps patients identify better and healthier alternatives.

article thumbnail

What Pharmacists Should Know About Medicare Open Enrollment 2023

Digital Pharmacist

All Part D plans must include at least two drugs from most drug categories/treatment classes and must cover all drugs available in the following categories: HIV/AIDS treatments. Provide Education and Guidance, the Earlier the Better. Antidepressants. Antipsychotic medications. Anticonvulsive treatments for seizure disorders.